NCT01147003

Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures

A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 93 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the efficacy and safety of BGG492 as adjunctive treatment in patients with partial onset seizures.

Conditions

• Partial Onset Seizures

Interventions

Type	Name	Description
DRUG	Investigational new drug, company code: BGG492
DRUG	Placebo
DRUG	Investigational new drug, company code: BGG492

Timeline

• Start date: 2010-06-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2010-06-22
• Last updated: 2020-12-17

Locations

51 sites across 10 countries: United States, Bulgaria, Germany, Hungary, Italy, Poland, Slovakia, South Korea, Switzerland, Taiwan